Personalis Market Cap 2018-2024 | PSNL
Personalis market cap history and chart from 2018 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Personalis market cap as of November 01, 2024 is $0.27B.
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.270B | $0.073B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $20.902B | 7.10 |
| Dr Reddy's Laboratories (RDY) | India | $12.399B | 18.57 |
| BridgeBio Pharma (BBIO) | United States | $4.791B | 0.00 |
| Bausch Health Cos (BHC) | Canada | $3.597B | 2.61 |
| Amphastar Pharmaceuticals (AMPH) | United States | $2.469B | 13.82 |
| Supernus Pharmaceuticals (SUPN) | United States | $1.872B | 377.44 |
| Taysha Gene Therapies (TSHA) | United States | $0.314B | 51.00 |
| Assembly Biosciences (ASMB) | United States | $0.107B | 0.00 |
| Acasti Pharma (GRCE) | Canada | $0.031B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.014B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.005B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |